Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM1A | O60341 | 4/20 | 0.52 |
| ▸ | MAOA | P21397 | 4/20 | 0.52 |
| ▸ | RCOR1 | Q9UKL0 | 2/20 | 0.50 |
| ▸ | MAOB | P27338 | 2/20 | 0.47 |
| ▸ | HTT | P42858 | 1/20 | 0.44 |
| ▸ | NPC1 | O15118 | 5/20 | 0.44 |
| ▸ | RAB9A | P51151 | 5/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | SMYD3 | Q9H7B4 | 2/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21471638 | 0.89 | KDM1A (0.66) | KDM1AMAOARCOR1MAOBHTT | |
| SCHEMBL19976189 | 0.87 | MAOB (0.64) | KDM1AMAOARCOR1MAOB | |
| SCHEMBL21471773 | 0.80 | KDM1A (0.53) | KDM1AMAOARCOR1 | |
| SCHEMBL20521778 | 0.79 | SMYD3 (0.46) | KDM1AMAOARCOR1MAOBHTT | |
| SCHEMBL12124434 | 0.79 | NPC1 (0.62) | HTTNPC1RAB9AKMT2ASMN1; SMN2 | |
| SCHEMBL21727185 | 0.77 | PTGS1 (0.45) | KDM1AMAOARCOR1HTTNPC1 | |
| Hydrochloric Acid SCHEMBL17158731 | 0.76 | MAOA (0.62) | KDM1AMAOARCOR1MAOBNPC1 | |
| Hydrochloric Acid SCHEMBL17158732 | 0.76 | MAOA (0.62) | KDM1AMAOARCOR1MAOBNPC1 | |
| SCHEMBL19156000 | 0.76 | DAO (0.50) | KDM1AMAOAMAPT | |
| SCHEMBL23505853 | 0.76 | RAB9A (0.64) | KDM1ARCOR1HTTNPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10968213-B2 | Cyclopropanamine compound and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2021-04-06 | — | — | US | disclosed |
| US-20190315735-A1 | CYCLOPROPANAMINE COMPOUND AND USE THEREOF | TAKEDA PHARMACEUTICALS CO (JP) | 2019-10-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190315735-A1 | CYCLOPROPANAMINE COMPOUND AND USE THEREOF | KDM1A, KDM1B, KDM2A | KDM1A 1/4885MAOA 493/4885RCOR1 218/4885 |
| US-10968213-B2 | Cyclopropanamine compound and use thereof | KDM1A, KDM1B, KDM2A | KDM1A 1/4885MAOA 493/4885RCOR1 218/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.